Guangdong Lifestrong Pharmacy Co., Ltd. (SHE:301111)
China · Delayed Price · Currency is CNY 21.39
-0.55 (-2.51%)
Sep 10, 2026, 3:04 PM CST
SHE:301111 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 304.04 | 313.14 | 274.19 | 292.15 | 283.29 | 349.44 |
Other Revenue | 0.58 | 1.5 | 4.45 | 0.25 | 0.05 | 0.35 |
| 304.63 | 314.64 | 278.64 | 292.4 | 283.34 | 349.79 | |
Revenue Growth | 8.39% | 12.92% | -4.71% | 3.20% | -19.00% | 2.59% |
Cost of Revenue | 129.41 | 123.78 | 84.37 | 94.55 | 92.74 | 107.53 |
Gross Profit | 175.21 | 190.86 | 194.27 | 197.85 | 190.6 | 242.26 |
Selling, General & Admin | 167.36 | 197 | 188.54 | 164.31 | 155.88 | 165.38 |
Research & Development | 8.7 | 8.49 | 8.41 | 8.44 | 9.16 | 10.87 |
Other Operating Expenses | 3.87 | 4.22 | 3.03 | -0.62 | 1.72 | 4.71 |
Operating Expenses | 178.38 | 209.81 | 200.22 | 173.39 | 166.77 | 181.75 |
Operating Income | -3.16 | -18.95 | -5.96 | 24.46 | 23.83 | 60.51 |
Interest Expense | -1.49 | -3.06 | -2.46 | -0.37 | -0.03 | -0.06 |
Interest & Investment Income | 13.14 | 14.75 | 12.45 | 14.6 | 14.25 | 4.03 |
Other Non Operating Income (Expenses) | 0.55 | -0.11 | -0.06 | -1.01 | -0.03 | -0.04 |
EBT Excluding Unusual Items | 9.04 | -7.37 | 3.97 | 37.68 | 38.03 | 64.44 |
Gain (Loss) on Sale of Investments | 0.63 | 0.52 | 1.67 | 2.78 | 2.93 | 1.55 |
Gain (Loss) on Sale of Assets | 0.02 | - | - | - | -0.33 | -0.01 |
Asset Writedown | -5.1 | -4.12 | -5.64 | -3.8 | -8.4 | -5.69 |
Other Unusual Items | 1.16 | 1.21 | -0.14 | 0.63 | 2.52 | 6.44 |
Pretax Income | 5.74 | -9.76 | -0.14 | 37.29 | 34.75 | 66.72 |
Income Tax Expense | 2.68 | -0.63 | -1.38 | 4.76 | 1.33 | 9.54 |
Earnings From Continuing Operations | 3.06 | -9.13 | 1.24 | 32.53 | 33.42 | 57.18 |
Minority Interest in Earnings | 2.87 | 4.64 | 2.92 | 0.97 | 0 | - |
Net Income | 5.93 | -4.49 | 4.16 | 33.5 | 33.42 | 57.18 |
Net Income to Common | 5.93 | -4.49 | 4.16 | 33.5 | 33.42 | 57.18 |
Net Income Growth | - | - | -87.58% | 0.25% | -41.56% | -8.54% |
Shares Outstanding (Basic) | 153 | 150 | 139 | 160 | 159 | 119 |
Shares Outstanding (Diluted) | 153 | 150 | 139 | 160 | 159 | 119 |
Shares Change | 12.66% | 7.83% | -13.02% | 0.25% | 33.59% | -0.92% |
EPS (Basic) | 0.04 | -0.03 | 0.03 | 0.21 | 0.21 | 0.48 |
EPS (Diluted) | 0.04 | -0.03 | 0.03 | 0.21 | 0.21 | 0.48 |
EPS Growth | - | - | -85.71% | 0% | -56.25% | -7.69% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -0.96 | 0.8 | -34.69 | -51.41 | 64.34 | 68.54 |
Free Cash Flow Per Share | -0.01 | 0.01 | -0.25 | -0.32 | 0.40 | 0.57 |
Dividend Per Share | 0.050 | 0.050 | 0.050 | 0.100 | 0.100 | 0.160 |
Dividend Growth | 0% | 0% | -50.00% | 0% | -37.50% | - |
Gross Margin | 57.52% | 60.66% | 69.72% | 67.66% | 67.27% | 69.26% |
Operating Margin | -1.04% | -6.02% | -2.14% | 8.37% | 8.41% | 17.30% |
Profit Margin | 1.94% | -1.43% | 1.49% | 11.46% | 11.79% | 16.35% |
Free Cash Flow Margin | -0.32% | 0.26% | -12.45% | -17.58% | 22.71% | 19.59% |
EBITDA | 6.34 | -9.18 | 5.42 | 35.21 | 35.14 | 74.6 |
EBITDA Margin | 2.08% | -2.92% | 1.94% | 12.04% | 12.40% | 21.33% |
D&A For EBITDA | 9.5 | 9.77 | 11.38 | 10.75 | 11.31 | 14.1 |
EBIT | -3.16 | -18.95 | -5.96 | 24.46 | 23.83 | 60.51 |
EBIT Margin | -1.04% | -6.02% | -2.14% | 8.37% | 8.41% | 17.30% |
Effective Tax Rate | 46.71% | - | - | 12.76% | 3.83% | 14.30% |
Revenue as Reported | 159.86 | 314.64 | 278.64 | 292.4 | 283.34 | 349.79 |